Vaxcyte reported second-quarter results showing a net loss of $284.3 million, nearly double the $166.6 million loss from a year earlier. The clinical-stage vaccine maker has fully enrolled three Phase 3 trials for its lead pneumococcal candidate VAX-31, with 6,191 adults dosed across the studies. Research and development spending rose to $267.9 million from $194.2 million, driven by manufacturing preparation and trial costs. The company held $2.5 billion in cash and investments as of 30 June. The first major data readout from the OPUS-1 trial, comparing VAX-31 against Prevnar 20 and Capvaxive, is expected in the fourth quarter of 2026. Results from OPUS-2 and OPUS-3 will follow in the first half of 2027. Hedge fund ownership declined from 57 to 47 funds, whilst short interest stands at 10% of the float.

Vaxcyte has appointed Luis Jodar and David McAvoy as chief medical officer and chief legal officer, respectively. The clinical-stage vaccine innovation company also narrowed its guidance for topline data from the VAX-31 adult Phase 3 OPUS-1 trial, now expecting results by the end of October 2026. Jodar joins from Pfizer, where he spent 17 years, most recently as senior vice president and chief medical officer for vaccines and infectious diseases. He led clinical development and regulatory strategy for programmes including Prevnar 13 and Prevnar 20. McAvoy previously served as chief legal officer at Teva. The appointments come as Vaxcyte prepares for its planned Biologics Licence Application submission and potential launch of VAX-31.

Vaxcyte shares rose 8.7% after completing enrollment for three Phase 3 adult trials of its VAX-31 pneumococcal vaccine candidate and a Phase 2 infant study. The company also announced plans to begin a Phase 1 adult trial for its VAX-A1 Group A Strep programme. The milestone reduces execution risk whilst advancing Vaxcyte's two-pillar strategy targeting both adult and paediatric pneumococcal markets. The company's narrative projects $224.6 million revenue by 2029, representing an earnings increase of approximately $794.7 million from current levels. Some analysts forecast Vaxcyte reaching $424 million revenue by 2029. Key near-term catalysts include OPUS-1 Phase 3 adult data readout, though higher research and manufacturing spending may pressure the company's cash runway before late-stage outcomes are determined.